These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 19499721)

  • 41. Is tigecycline drug of choice for cIAI and cSSTI?
    Hosgor-Limoncu M
    Int J Clin Pract; 2013 Jun; 67(6):492-3. PubMed ID: 23679901
    [No Abstract]   [Full Text] [Related]  

  • 42. Antimicrobial activity and pharmacokinetics/pharmacodynamics of the novel glycylcycline, tigecycline.
    Peterson LR
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):163-4. PubMed ID: 16105559
    [No Abstract]   [Full Text] [Related]  

  • 43. Efficacy and Safety of Tigecycline for Patients with Hospital-Acquired Pneumonia.
    Xu L; Wang YL; Du S; Chen L; Long LH; Wu Y
    Chemotherapy; 2016; 61(6):323-30. PubMed ID: 27144279
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
    Vasilev K; Reshedko G; Orasan R; Sanchez M; Teras J; Babinchak T; Dukart G; Cooper A; Dartois N; Gandjini H; Orrico R; Ellis-Grosse E;
    J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effectiveness and safety of tigecycline: focus on use for approved indications.
    Vardakas KZ; Rafailidis PI; Falagas ME
    Clin Infect Dis; 2012 Jun; 54(11):1672-4. PubMed ID: 22431809
    [No Abstract]   [Full Text] [Related]  

  • 46. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis.
    Tasina E; Haidich AB; Kokkali S; Arvanitidou M
    Lancet Infect Dis; 2011 Nov; 11(11):834-44. PubMed ID: 21784708
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of tigecycline pleurodesis: a comparative experimental study.
    Daddi N; Vannucci J; Maggio C; Giontella A; Bravi I; Marziani F; Capozzi R; Ragusa M; Bufalari A; Puma F
    J Surg Res; 2011 Aug; 169(2):e109-18. PubMed ID: 20934718
    [TBL] [Abstract][Full Text] [Related]  

  • 48. True incidence of tigecycline-induced pancreatitis: how many cases are we missing?
    Davido B; Shourick J; Makhloufi S; Dinh A; Salomon J
    J Antimicrob Chemother; 2016 Oct; 71(10):2994-5. PubMed ID: 27365188
    [No Abstract]   [Full Text] [Related]  

  • 49. An update on tetracyclines.
    Shlaes DM
    Curr Opin Investig Drugs; 2006 Feb; 7(2):167-71. PubMed ID: 16499287
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia.
    Freire AT; Melnyk V; Kim MJ; Datsenko O; Dzyublik O; Glumcher F; Chuang YC; Maroko RT; Dukart G; Cooper CA; Korth-Bradley JM; Dartois N; Gandjini H;
    Diagn Microbiol Infect Dis; 2010 Oct; 68(2):140-51. PubMed ID: 20846586
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tigecycline: benefits and risks.
    Cai Y; Wang R
    Lancet Infect Dis; 2011 Nov; 11(11):804-5. PubMed ID: 21784707
    [No Abstract]   [Full Text] [Related]  

  • 52. Anti-anaerobic activity of serum from patients treated with tigecycline for skin/soft tissue infections.
    Stein GE; Tyrrell KL; Dybas LA; Citron DM; Nicolau DP; Goldstein EJ
    Anaerobe; 2011 Aug; 17(4):213-5. PubMed ID: 21376823
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy of tigecycline alone and with rifampin in foreign-body infection by methicillin-resistant Staphylococcus aureus.
    Garrigós C; Murillo O; Euba G; Verdaguer R; Tubau F; Cabellos C; Cabo J; Ariza J
    J Infect; 2011 Sep; 63(3):229-35. PubMed ID: 21763722
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety and tolerability of tigecycline for the treatment of complicated skin and soft-tissue and intra-abdominal infections: an analysis based on five European observational studies.
    Guirao X; Sánchez García M; Bassetti M; Bodmann KF; Dupont H; Montravers P; Heizmann WR; Capparella MR; Simoneau D; Eckmann C
    J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii37-44. PubMed ID: 23772045
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint.
    Burkhardt O; Rauch K; Kaever V; Hadem J; Kielstein JT; Welte T
    Int J Antimicrob Agents; 2009 Jul; 34(1):101-2. PubMed ID: 19278835
    [No Abstract]   [Full Text] [Related]  

  • 56. Efficacy of tigecycline for the treatment of complicated skin and soft-tissue infections in real-life clinical practice from five European observational studies.
    Montravers P; Bassetti M; Dupont H; Eckmann C; Heizmann WR; Guirao X; García MS; Capparella MR; Simoneau D; Bodmann KF
    J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii15-24. PubMed ID: 23772042
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tigecycline.
    Pankey GA
    J Antimicrob Chemother; 2005 Sep; 56(3):470-80. PubMed ID: 16040625
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections - the European experience.
    Fomin P; Koalov S; Cooper A; Babinchak T; Dartois N; De Vane N; Castaing N; Tellado J;
    J Chemother; 2008 Oct; 20 Suppl 1():12-9. PubMed ID: 19036670
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Re-defining tigecycline therapy.
    De Rosa FG; Corcione S; Di Perri G; Scaglione F
    New Microbiol; 2015 Apr; 38(2):121-36. PubMed ID: 25915055
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tigecycline for treating ventilator-associated pneumonia: a practical perspective.
    Curcio D
    Diagn Microbiol Infect Dis; 2011 Apr; 69(4):466-7. PubMed ID: 21396549
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.